TY - JOUR
T1 - Correlation between change in central subfield thickness and change in visual acuity in macular edema due to retinal vein occlusion
T2 - post hoc analysis of COPERNICUS, GALILEO, and VIBRANT
AU - Gu, Sophie Z.
AU - Nanegrungsunk, Onnisa
AU - Bressler, Susan B.
AU - Du, Weiming
AU - Amer, Fouad
AU - Moini, Hadi
AU - Bressler, Neil M.
N1 - Funding Information:
This project was funded by the Regeneron Pharmaceuticals, Inc. (Tarrytown, New York) and by philanthropic grants awarded to the Johns Hopkins University School of Medicine (Principal investigator: Dr. Neil Bressler). Regeneron Pharmaceuticals, Inc. participated in design of the study, data analysis, and preparation of the manuscript.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Purpose: Assess correlation between change in central subfield thickness (CST) and change in best-corrected visual acuity (BCVA) in eyes with macular edema due to retinal vein occlusion (RVO) that received intravitreal aflibercept injections (IAI). Methods: Post hoc analysis of COPERNICUS and GALILEO trials for CRVO and VIBRANT trial for BRVO with relationships determined using Pearson correlation coefficient. Results: In COPERNICUS, correlations (r) between change in CST and change in BCVA from baseline at weeks 12, 24, 52, and 100 were −0.36 (95% CI: −0.52, −0.18; P < 0.001), −0.38 (95% CI: −0.53, −0.20; P < 0.001), −0.44 (95% CI: −0.58, −0.27; P < 0.001), and −0.41 (95% CI: −0.56, −0.23; P < 0.001), respectively. CST changes accounted for only 21% of the variance in BCVA changes; every 100-µm decrease in CST was associated with a 2.1-letter increase in BCVA (P = 0.003). Similar findings were noted for GALILEO (r, −0.45 to −0.23) and VIBRANT (r, −0.36 to −0.32) trials. Conclusion: In eyes treated with IAI for macular edema due to RVO, correlation between change in CST and change in BCVA was weak to moderate. While change in CST may be helpful in determining the need for anti-VEGF therapy, these findings do not support using changes in CST as a surrogate for changes in visual acuity outcomes. [Figure not available: see fulltext.]
AB - Purpose: Assess correlation between change in central subfield thickness (CST) and change in best-corrected visual acuity (BCVA) in eyes with macular edema due to retinal vein occlusion (RVO) that received intravitreal aflibercept injections (IAI). Methods: Post hoc analysis of COPERNICUS and GALILEO trials for CRVO and VIBRANT trial for BRVO with relationships determined using Pearson correlation coefficient. Results: In COPERNICUS, correlations (r) between change in CST and change in BCVA from baseline at weeks 12, 24, 52, and 100 were −0.36 (95% CI: −0.52, −0.18; P < 0.001), −0.38 (95% CI: −0.53, −0.20; P < 0.001), −0.44 (95% CI: −0.58, −0.27; P < 0.001), and −0.41 (95% CI: −0.56, −0.23; P < 0.001), respectively. CST changes accounted for only 21% of the variance in BCVA changes; every 100-µm decrease in CST was associated with a 2.1-letter increase in BCVA (P = 0.003). Similar findings were noted for GALILEO (r, −0.45 to −0.23) and VIBRANT (r, −0.36 to −0.32) trials. Conclusion: In eyes treated with IAI for macular edema due to RVO, correlation between change in CST and change in BCVA was weak to moderate. While change in CST may be helpful in determining the need for anti-VEGF therapy, these findings do not support using changes in CST as a surrogate for changes in visual acuity outcomes. [Figure not available: see fulltext.]
KW - Central subfield thickness
KW - Macular edema
KW - Retinal vein occlusion
KW - Visual acuity
UR - http://www.scopus.com/inward/record.url?scp=85132785647&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132785647&partnerID=8YFLogxK
U2 - 10.1007/s00417-022-05697-4
DO - 10.1007/s00417-022-05697-4
M3 - Article
C2 - 35748935
AN - SCOPUS:85132785647
SN - 0721-832X
VL - 260
SP - 3799
EP - 3807
JO - Graefe's Archive for Clinical and Experimental Ophthalmology
JF - Graefe's Archive for Clinical and Experimental Ophthalmology
IS - 12
ER -